Sonoma Pharmaceuticals Q4 Revenue Rises 48% with US Sales Up 194%
SNOA•Sonoma Pharmaceuticals delivered Q4 revenue of $5.6 million, up 48% year-over-year, with US sales surging 194% to $2.0 million. Net loss narrowed 25% to $0.6 million in Q4 and full-year EBITDA loss improved 38% to $2.1 million, while FY revenue rose 37% to $19.5 million.
1. Q4 Financial Performance
Sonoma recorded $5.6 million in fourth-quarter revenue, a 48% increase from the prior year, driven by a 194% surge in US sales to $2.0 million. Gross margin was 39%, net loss narrowed by 25% to $0.6 million and EBITDA loss improved 66% to $0.2 million.
2. Full-Year 2026 Results
Annual revenue rose 37% to $19.5 million with gross margin steady at 38%. Net loss improved 8% to $3.2 million while EBITDA loss fell 38% to $2.1 million, reflecting operational discipline and cost management.
3. Business Highlights
In October 2025, Sonoma’s Microcyn® facial spray gained FDA MoCRA registration and a new HOCl wound cleanser launched for Medline’s hospital and home healthcare channels. Reliefacyn® Advanced hydrogel earned National Psoriasis Foundation and National Rosacea Society seals in 2025.
4. Financial Position
As of March 31, 2026, Sonoma held $2.4 million in cash and cash equivalents, supporting ongoing regulatory initiatives, product innovation and global distribution expansion.
